

# Anti-Treponema pallidum ELISA (IgG)

## Test instruction

ORDER NO.	ANTIBODIES AGAINST	IG-CLASS	SUBSTRATE	FORMAT
EI 2111-9601 G	Treponema pallidum	IgG	Ag-coated microplate wells	96 x 01 (96)

**Indication:** Infection with *Treponema pallidum*, associated diseases: Lues.

**Principles of the test:** The ELISA test kit provides a semiquantitative or quantitative in vitro assay for human antibodies of the IgG class against *Treponema pallidum* in serum or plasma. The test kit contains microtiter strips each with 8 break-off reagent wells coated with purified recombinant antigens of *Treponema pallidum*. In the first reaction step, diluted patient samples are incubated in the wells. In the case of positive samples, specific IgG antibodies (also IgA and IgM) will bind to the antigens. To detect the bound antibodies, a second incubation is carried out using an enzyme-labelled anti-human IgG (enzyme conjugate), catalysing a colour reaction.

### Contents of the test kit:

Component	Colour	Format	Symbol
<b>1. Microplate wells</b> coated with antigens: 12 microplate strips each containing 8 individual break-off wells in a frame, ready for use	---	12 x 8	<span style="border: 1px solid black; padding: 2px;">STRIPS</span>
<b>2. Calibrator 1</b> 200 RU/ml (IgG, human), ready for use	dark red	1 x 2.0 ml	<span style="border: 1px solid black; padding: 2px;">CAL 1</span>
<b>3. Calibrator 2</b> 20 RU/ml (IgG, human), ready for use	red	1 x 2.0 ml	<span style="border: 1px solid black; padding: 2px;">CAL 2</span>
<b>4. Calibrator 3</b> 2 RU/ml (IgG, human), ready for use	light red	1 x 2.0 ml	<span style="border: 1px solid black; padding: 2px;">CAL 3</span>
<b>5. Positive control</b> (IgG, human), ready for use	blue	1 x 2.0 ml	<span style="border: 1px solid black; padding: 2px;">POS CONTROL</span>
<b>6. Negative control</b> (IgG, human), ready for use	green	1 x 2.0 ml	<span style="border: 1px solid black; padding: 2px;">NEG CONTROL</span>
<b>7. Enzyme conjugate</b> peroxidase-labelled anti-human IgG (rabbit), ready for use	green	1 x 12 ml	<span style="border: 1px solid black; padding: 2px;">CONJUGATE</span>
<b>8. Sample buffer</b> ready for use	light blue	1 x 100 ml	<span style="border: 1px solid black; padding: 2px;">SAMPLEBUFFER</span>
<b>9. Wash buffer</b> 10x concentrate	colourless	1 x 100 ml	<span style="border: 1px solid black; padding: 2px;">WASHBUFFER 10x</span>
<b>10. Chromogen/substrate solution</b> TMB/H <sub>2</sub> O <sub>2</sub> , ready for use	colourless	1 x 12 ml	<span style="border: 1px solid black; padding: 2px;">SUBSTRATE</span>
<b>11. Stop solution</b> 0.5 M sulphuric acid, ready for use	colourless	1 x 12 ml	<span style="border: 1px solid black; padding: 2px;">STOP SOLUTION</span>
<b>12. Test instruction</b>	---	1 booklet	
<b>13. Protocol with reference values</b>	---	1 protocol	
<b>14. Protective foil</b>	---	2 pieces	

<span style="border: 1px solid black; padding: 2px;">LOT</span> Lot	<input type="checkbox"/>	<input type="checkbox"/> Storage temperature
<span style="border: 1px solid black; padding: 2px;">IVD</span> In vitro determination	<input type="checkbox"/>	<input type="checkbox"/> Unopened usable until

**Storage and stability:** The test kit has to be stored at a temperature between +2°C to +8°C. Do not freeze. Unopened, all test kit components are stable until the indicated expiry date.

**Waste disposal:** Patient samples, calibrators, controls and incubated microplate strips should be handled as infectious waste. All reagents should be disposed of according to official regulations.



## Preparation and stability of the reagents

**Note:** All reagents must be brought to room temperature (+18°C to +25°C) approx. 30 minutes before use. After first use, the reagents are stable until the indicated expiry date if stored at +2°C to +8°C and protected from contamination, unless stated otherwise below. The thermostat adjusted ELISA incubator must be set at 37 °C +/- 1 °C

- **Coated wells:** Ready for use. Tear open the resealable protective wrapping of the microplate at the recesses above the grip seam. Do not open until the microplate has reached room temperature to prevent the individual strips from moistening. Immediately replace the remaining wells of a partly used microplate in the protective wrapping and tightly seal with the integrated grip seam (Do not remove the desiccant bag).  
Once the protective wrapping has been opened for the first time, the wells coated with antigens can be stored in a dry place and at a temperature between +2°C and +8°C for 4 months.
- **Calibrators and controls:** Ready for use. The reagents must be mixed thoroughly before use.
- **Enzyme conjugate:** Ready for use. The enzyme conjugate must be mixed thoroughly before use.
- **Sample buffer:** Ready for use.
- **Wash buffer:** The wash buffer is a 10x concentrate. If crystallization occurs in the concentrated buffer, warm it to 37°C and mix well before diluting. The quantity required should be removed from the bottle using a clean pipette and diluted with deionized or distilled water (1 part reagent plus 9 parts distilled water).  
For example: For 1 microplate strip, 5 ml concentrate plus 45 ml water.  
The working strength wash buffer is stable for 4 weeks when stored at +2°C to +8°C and handled properly.
- **Chromogen/substrate solution:** Ready for use. Close the bottle immediately after use, as the contents are sensitive to light. The chromogen/substrate solution must be clear on use. Do not use the solution if it is blue coloured.
- **Stop solution:** Ready for use.

**Warning:** Calibrators and controls used have been tested negative for HBsAg, anti-HCV, anti-HIV-1 and anti-HIV-2 using enzyme immunoassays and indirect immunofluorescence methods. Nonetheless, all materials should be treated as being a potential infection hazard and should be handled with care. Some of the reagents contain the toxic agent sodium azide. Avoid skin contact.

## Preparation and stability of the patient samples

**Sample material:** Human serum or EDTA, heparin or citrate plasma.

**Stability:** Patient samples to be investigated can generally be stored at +2°C to +8°C for up to 14 days. Diluted samples should be incubated within one working day.

**Sample dilution: Patient samples** are diluted **1:101** sample buffer. For example: dilute 10 µl serum in 1.0 ml sample buffer and mix well by vortexing (sample pipettes are not suitable for mixing).

**NOTE:** Calibrators and controls are prediluted and ready for use, do not dilute them.



## Incubation

For **semiquantative analysis** incubate **calibrator 2** along with the positive and negative controls and patient samples. For **quantitative analysis** incubate **calibrators 1, 2 and 3** along with the positive and negative controls and patient samples.

**Sample incubation:** (1. step) Transfer 100 µl of the calibrators, positive and negative controls or diluted patient samples into the individual microplate wells according to the pipetting protocol.  
For manual processing of microplate wells, cover the finished test plate with the protective foil. When using an automated microplate processor for incubation, follow the instrument manufacturer's recommendations with regard to microwell plate sealing.  
Incubate **60 minutes** at 37°C ± 1°C.

**Wash:** Manual: Remove the protective foil and empty the wells and subsequently wash 3 times using 300 µl of working strength wash buffer for each wash.  
Automatic: Remove the protective foil and empty the wells and subsequently wash 3 times with 450 µl working strength wash buffer (program setting: e.g. TECAN Columbus Washer "Overflow Modus").

Leave the wash buffer in each well for 30 to 60 seconds per washing cycle, then empty the wells. After washing (manual and automated tests), thoroughly dispose of all liquid from the microplate by tapping it on absorbent paper with the openings facing downwards to remove all residual wash buffer.

Attention: Residual liquid (> 10 µl) in the reagent wells after washing can interfere with the substrate and lead to false low extinction values. Insufficient washing (e.g., less than 3 wash cycles, too small wash buffer volumes, or too short reaction times) can lead to false high extinction values.  
Free positions on the microplate strip should be filled with blank wells of the same plate format as that of the parameter to be investigated.

**Conjugate incubation:** (2. step) Pipette 100 µl of enzyme conjugate (peroxidase-labelled anti-human IgG) into each of the microplate wells. Incubate for **30 minutes** at room temperature (+18°C to 25°C).

**Wash:** Empty the wells. Wash as described above.

**Substrate incubation:** (3. step) Pipette 100 µl of chromogen/substrate solution into each of the microplate wells. Incubate for **15 minutes** at room temperature (+18°C to 25°C) (protect from direct sunlight).

**Stopping the reaction:** Pipette 100 µl of stop solution into each of the microplate wells in the same order and at the same speed as the chromogen/substrate solution was introduced.

**Measurement:** **Photometric measurement** of the colour intensity should be made at a wavelength of 450 nm and a reference wavelength between 620 nm and 650 nm **within 30 minutes of adding the stop solution**. Prior to measuring, slightly shake the microplate to ensure a homogeneous distribution of the solution.



## Pipetting protocol

	1	2	3	4	5	6	7	8	9	10	11	12
A	K 2	P 6	P 14	P 22			K 1	P 4	P 12	P 20		
B	pos.	P 7	P 15	P 23			K 2	P 5	P 13	P 21		
C	neg.	P 8	P 16	P 24			K 3	P 6	P 14	P 22		
D	P 1	P 9	P 17				pos.	P 7	P 15	P 23		
E	P 2	P 10	P 18				neg.	P 8	P 16	P 24		
F	P 3	P 11	P 19				P 1	P 9	P 17			
G	P 4	P 12	P 20				P 2	P 10	P 18			
H	P 5	P 13	P 21				P 3	P 11	P 19			

The pipetting protocol for microtiter strips 1-4 is an example for the **semiquantitative analysis** of 24 patient samples (P 1 to P 24).

The pipetting protocol for microtiter strips 7-10 is an example for the **quantitative analysis** of 24 patient samples (P 1 to P 24).

The calibrators (C 1 to C 3), the positive (pos.) and negative (neg.) controls, and the patient samples have each been incubated in one well. The reliability of the ELISA test can be improved by duplicate determinations for each sample.

The wells can be broken off individually from the strips. This makes it possible to adjust the number of test substrates used to the number of samples to be examined and minimizes reagent wastage.

Both positive and negative controls serve as internal controls for the reliability of the test procedure. They should be assayed with each test run.

## Calculation of results

**Semiquantitative:** Results can be evaluated semiquantitatively by calculating a ratio of the extinction value of the control or patient sample over the extinction value of the calibrator 2. Calculate the ratio according the following formula:


$$\frac{\text{Extinction of the control or patient sample}}{\text{Extinction of calibrator 2}} = \text{Ratio}$$

EUROIMMUN recommends interpreting results as follows:

<b>Ratio &lt;0.8:</b>	<b>negative</b>
<b>Ratio ≥0.8 to &lt;1.1:</b>	<b>borderline</b>
<b>Ratio ≥1.1:</b>	<b>positive</b>

In cases of borderline test results, an additional patient sample should be taken 7 days later and re-tested in parallel with the first patient sample. The results of both samples allow proper evaluation of titer changes.

**Quantitative:** The standard curve from which the concentration of antibodies in the patient samples can be taken is obtained by point-to-point plotting of the extinction values measured for the 3 calibration sera against the corresponding units (linear/linear). Use "point-to-point" plotting for calculation of the standard curve by computer. The following plot is an example of a typical calibration curve. Please do not use this curve for the determination of antibody concentrations in patient samples.



If the extinction of a serum sample lies above the value of calibrator 1 (200 RU/ml). The result should be given as ">200 RU/ml". It is recommended that the sample be re-tested at a dilution of 1:400. The result in RU/ml read from the calibration curve for this sample must then be multiplied by a factor of 4.

The upper limit of the normal range of non-infected persons (**cut-off value**) recommended by EUROIMMUN is **20 relative units (RU/ml)**. EUROIMMUN recommends interpreting results as follows:

<16 RU/ml:	<b>negative</b>
≥16 to <22 RU/ml:	<b>borderline</b>
≥22 RU/ml:	<b>positive</b>

For duplicate determinations the mean of the two values should be taken. If the two values deviate substantially from one another the sample should be retested.

For diagnosis, the clinical symptoms of the patient should always be taken into account along with the serological results.

## Test characteristics

**Calibration:** As no quantified international reference serum exists for antibodies against *Treponema pallidum*, the calibration is performed in relative units (RU). The international standard for Human Syphilis Serum; 1. international standard preparation SSI code number HS reacts with >200 RU/ml. Using dilution curve result would be 1882 RU/ml.

For every group of tests performed, the extinction values of the calibrators and the relative units and/or ratio determined for the positive and negative controls must lie within the limits stated for the relevant test kit lot. A protocol containing these reference values is included. If the values specified for the control sera are not achieved, the test results may be inaccurate and the test should be repeated.

The activity of the enzyme used is temperature-dependent and the extinction values may vary if a thermostat is not used. The higher the room temperature during substrate incubation, the greater will be the extinction values. Corresponding variations apply also to the incubation times. However, the calibrators are subject to the same influences, with the result that such variations will be largely compensated in the calculation of the result.

**Antigens:** The microplate wells were coated with a mixture of four antigens of *Treponema pallidum*: p15, p17, p47 and TmpA. The corresponding cDNAs were expressed in *E. coli* as recombinant antigens.



**Linearity:** The linearity of the Anti-Treponema pallidum ELISA (IgG) was determined by assaying 4 serial dilutions of 6 serum samples. The linear regression was calculated and  $R^2$  amounts to  $> 0.95$  in all samples. The Anti-Treponema pallidum ELISA (IgG) is linear at least in the tested concentration range (19 RU/ml to 166 RU/ml).

**Detection limit:** The detection limit is defined as a value of three times the standard deviation of an analyte-free sample and is the smallest detectable antibody titer. The lower detection limit of the Anti-Treponema pallidum ELISA (IgG) is 0.3 RU/ml.

**Cross reactivity:** The quality of the antigen used ensures a high specificity and sensitivity of the ELISA. Sera from patients with infections caused by various agents were investigated with the Anti-Treponema pallidum ELISA (IgG). This ELISA showed no cross reactivity.

Parameter	HSV-1	EBV-CA	CMV	VZV	Adenovirus	RSVi	Parainfl. Pool	Influenza A
n	12	12	12	12	12	12	12	12
Anti-Treponema pallidum ELISA (IgG)	0	0	0	0	0	0	0	0

Parameter	Influenza B	Mycoplasma pn.	Mumps	Measles	Rubella	Toxoplasma gondii	Chlamydia pneu.	Heliobacter pyl.
n	12	12	12	12	12	12	12	12
Anti-Treponema-pallidum-ELISA (IgG)	0	0	0	0	0	0	0	0

**Interference:** Haemolytic, lipaemic and icteric samples showed no influence at the result up to a concentration of 10 mg/ml for hemoglobin, 20 mg/ml for triglycerides and 0.4 mg/ml for bilirubin in this ELISA.

**Reproducibility:** The reproducibility of the test was investigated by determining the intra- and inter-assay coefficients of variation using 3 sera. The intra-assay CVs are based on 20 determinations and the inter-assay CVs on 4 determinations performed in 6 different test runs.

<i>Intra-assay variation, n = 20</i>		
Serum	Mean value (RU/ml)	CV (%)
1	45	3.1
2	139	1.7
3	146	1.7

<i>Inter-assay variation, n = 4 x 6</i>		
Serum	Mean value (RU/ml)	CV (%)
1	43	5.2
2	145	3.2
3	150	2.8

**Specificity and sensitivity:** 75 clinically characterized patient samples (interlaboratory test samples from INSTAND, Labquality Finland) were examined with the EUROIMMUN Anti-Treponema pallidum ELISA (IgG). The test showed a specificity and a sensitivity of 100% each. Values for 2 of the samples were borderline and were not included in the calculation.

n = 75		INSTAND / LABQUALITY		
		positive	borderline	negative
EUROIMMUN ELISA	positive	46	0	0
	borderline	2	0	0
	negative	0	0	27



139 clinically characterized patient samples were examined with the EUROIMMUN Anti-Treponema pallidum ELISA (IgG). The specificity with respect to the reference method was 100%, with a sensitivity of 98.6%.

n = 139		TPHA	
		positive	negative
EUROIMMUN ELISA	positive	137	0
	negative	2	0

**Reference range:** The levels of the anti-Treponema pallidum antibodies (IgG) were analyzed with this EUROIMMUN ELISA in a panel of 500 healthy blood donors. With a cut-off of 20 RU/ml, 0.4 % of the blood donors were anti-Treponema pallidum positive (IgG) which reflects the known percentage of infections in adults.

### Limitations of the procedure

The test is not intended to be used for the determination of suitability for transfusion, transplantation or cell administration.

### Clinical significance

**Treponema pallidum** is a helically wound bacteria of the Spirochaeta family [1]. This family includes five genera: borrelia, spirochaeta, cristispira, treponema and leptospira. Treponema pallidum is the causative agent of syphilis or lues, a chronic infectious disease. The subspecies T. pallidum endemicum causes venereal syphilis; T. pallidum pertenue leads to a non-venereal infection occurring in tropical regions called framboesia; T. pallidum carateum is the causative agent of Pinta [2, 3, 4].

In 1905 Fritz Schaudinn (German zoologist, 1871-1906) and Erich Hoffmann (German dermatologist, 1868-1959) at the Charité in Berlin were the first to detect the causative agent of syphilis under the microscope. Spirochaeta were first found in 1913 by the Japanese microbiologist and physician Noguchi Hideyo (1876-1928) in the brain tissue of a patient with progressive paralysis [1].

Syphilis is transmitted from human to human during sexual acts via the mucosa [1, 5]. Indirect transmission by blood transfusions and wounds is also possible. During pregnancy and at birth the baby can become infected by the mother (syphilis connata) [1, 6, 7, 8, 9]. Syphilis is a known risk factor for abortions and stillbirths [7, 10].

**Primary stage:** The ulcer durum (hard-edged ulcer) is characteristic of the primary lesion of the syphilis (stage I) and normally occurs 3 weeks after infection, developing at the place of entry of the virus (e.g. penis) [1]. It is a painless ulcer, which contains large quantities of the pathogen and is therefore highly contagious. Typically, the defined, limited fibrous or crusted erosion has a raised hard edge. The possible swelling of the regional lymph nodes is painless and the lymph nodes remain displaceable. From that time on, the disease can be diagnosed e.g. using the TPHA test (Treponema pallidum haemagglutination assay). After 2 to 6 weeks the ulcer heals leaving a scar. The infection generally persists and develops into stage II [1].

**Secondary stage:** Approximately 8 weeks after the infection, the disease manifests itself with flu-like symptoms such as fever, fatigue or head and joint pains. In addition to a generalised swelling of the lymph nodes, 90% of patients show local or generalised skin disorders, which are accompanied by weak or no itching. At first, light pink patches form, which further evolve into hard, coppery nodules (papules). In the foreground are condylomata lata, broad papules, which mainly affect skin folds [1]. The liquid excreted by open and weeping papules is highly contagious. Additionally, various organ disorders may develop, for example, keratitis, iritis, hepatitis, vasculitis, and myocardial disorders [1].



All skin disorders (syphilids) heal after approximately 4 months. Secondary syphilis is followed by a clinically silent stage (syphilis latens), which can last for years [1].

**Tertiary stage:** Typical manifestations of a *Treponema pallidum* infection in stage III are large papules and ulcers on the skin and mucous membranes, as well as organ or visceral syphilis, including gummatous and interstitial inflammation, perivasculitis, cardiovascular syphilis, neurosyphilis (asymptomatic and symptomatic form), osteitis, and periosteitis.

**Quaternary stage:** Ten to thirty years after an untreated infection, 8% to 10% of patients experience severe neurological disorders such as neurosyphilis with progressive paralysis and Tabes dorsalis with severe mental and vegetational disorders [1].

The **diagnosis** of syphilis is based on clinical findings according to the disease stage, microscopic detection of the infectious agent (dark field), and the serological detection of antibodies against *Treponema pallidum* [1].

*Treponema pallidum pallidum* has a length of 5-15µm and a width of 0.2µm with 10-20 turns and can rotate around its longitudinal axis [1]. Due to its fine structure, it is difficult to be made visible under the microscope by staining. However, living bacteria can be investigated using dark field microscopy. Detection in cultures has not yet been achieved [1].

The TPHA (*Treponema pallidum* haemagglutination assay) is an assay for the indirect determination of antibodies against *Treponema pallidum*. Erythrocytes marked with proteins and polysaccharides of *Treponema pallidum* on their surface are mixed with patient serum. The presence of antibodies against *Treponema pallidum* in the patient serum causes agglutination of the erythrocytes (haemagglutination), which is visible to the naked eye [1, 11, 12].

If the screening test is positive, additional testing is recommended e.g. using an FTA-ABS assay. For further serological diagnosis, modern serological test methods such as anti-*Treponema pallidum* ELISA, Westernblot, e.g. EUROLINE WB, and IIFT have become widely accepted and have proven successful [1, 7, 8, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34]. Antibodies can be found in the serum and CSF, particularly in children having congenital syphilis [6, 8, 9, 20, 35]. Antibodies against cardiolipin serve as an activity marker of the infection (VDRL or RPR test, EUROLINE WB) [36, 37, 38, 39, 40, 41, 42].

## Literature references

1. Hahn H, Miksits K. **Treponemen**. In: Hahn, Falke, Kaufmann, Ullmann. Medizinische Mikrobiologie und Infektiologie. Springer 5. Auflage (2005).
2. Centurion-Lara A, Molini BJ, Godornes C, Sun E, Hevner K, Van Voorhis WC, Lukehart SA. **Molecular differentiation of *Treponema pallidum* subspecies**. J Clin Microbiol 44 (2006) 3377-3380.
3. Leader BT, Hevner K, Molini BJ, Barrett LK, Van Voorhis WC, Lukehart SA. **Antibody responses elicited against the *Treponema pallidum* repeat proteins differ during infection with different isolates of *Treponema pallidum* subsp. *Pallidum***. Infect Immun 71 (2003) 6054-6057.
4. Sun ES, Molini BJ, Barrett LK, Centurion-Lara A, Lukehart SA, Van Voorhis WC. **Subfamily I *Treponema pallidum* repeat protein family: sequence variation and immunity**. Microbes Infect 6 (2004) 725-737.
5. Pajaro MC, Barberis IL, Godino S, Pascual L, Aguero M. **Epidemiology of sexually transmitted diseases in Rio Cuarto, Argentina**. Rev Latinoam Microbiol 43 (2001) 157-160.
6. Sanchez PJ, Wendel GD, Norgard MV. **IgM antibody to *Treponema pallidum* in cerebrospinal fluid of infants with congenital syphilis**. Am J Dis Child 146 (1992) 1171-1175.
7. Pankratov OV, Saluk YV, Klimova LV. **Epidemiology of syphilis in pregnant women and congenital syphilis in Belarus**. Acta Dermatovenerol Alp Panonica Adriat 15 (2006) 35-38.





8. Michelow IC, Wendel GD Jr, Norgard MV, Zeray F, Leos NK, Alsaadi R, Sanchez PJ. **Central nervous system infection in congenital syphilis.** N Engl J Med 346 (2002) 1792-1798.
9. Rawstron SA, Mehta S, Bromberg K. **Evaluation of a Treponema pallidum-specific IgM enzyme immunoassay and Treponema pallidum western blot antibody detection in the diagnosis of maternal and congenital syphilis.** Sex Transm Dis 31 (2004) 123-126.
10. Folgosa E, Osman NB, Gonzalez C, Hagerstrand I, Bergstrom S, Ljungh A. **Syphilis seroprevalence among pregnant women and its role as a risk factor for stillbirth in Maputo, Mozambique.** Genitourin Med 72 (1996) 339-342.
11. Castro R, Prieto ES, Joao Aguas M, Jose Manata M, Botas J, Araujo C, Borges F, Aldir I, Exposto Fda L. **Evaluation of the Treponema pallidum particle agglutination technique (TP.PA) in the diagnosis of neurosyphilis.** J Clin Lab Anal 20 (2006) 233-238.
12. Manavi K, Young H, McMillan A. **The sensitivity of syphilis assays in detecting different stages of early syphilis.** Int J STD AIDS 17 (2006) 768-771.
13. Lewis LL, Taber LH, Baughn RE. **Evaluation of immunoglobulin M western blot analysis in the diagnosis of congenital syphilis.** J Clin Microbiol 28 (1990) 296-302.
14. Kaiser R, Rauer S. **Serodiagnosis of neuroborreliosis: comparison of reliability of three confirmatory assays.** Infection 27 (1999) 177-182.
15. Lewis LL, Taber LH, Baughn RE. **Evaluation of Immunoglobulin M Western Blot Analysis in the Diagnosis of Congenital Syphilis.** J Clin Microbiol 28 (1990) 296-302.
16. Muller F. **Treponema pallidum IgM enzyme-linked immunosorbent assay (TP-IgM-ELISA). Determination of organism-specific Treponema IgM antibodies in the serum of syphilis patients with and without central nervous system involvement of the infection.** [Article in German] Z Hautkr 58 (1983) 1689-1708.
17. Merlin S, Poncet F, Alacoque B, Guinet R, Andre J. **Treponemal antigens detected by immunoblotting with serum and CSF antibodies of neurosyphilitic patients.** Ann Inst Pasteur Microbiol 138 (1987) 709-717.
18. Rawstron SA, Mehta S, Bromberg K. **Evaluation of a Treponema pallidum-specific IgM enzyme immunoassay and Treponema pallidum western blot antibody detection in the diagnosis of maternal and congenital syphilis.** Sex Transm Dis 31 (2004) 123-126.
19. Kaiser R, Rauer S. **Serodiagnosis of neuroborreliosis: comparison of reliability of three confirmatory assays.** Infection 27 (1999) 177-182.
20. Schmitz JL, Gertis KS, Mauney C, Stamm LV, Folds JD. **Laboratory diagnosis of congenital syphilis by immunoglobulin M (IgM) and IgA immunoblotting.** Clin Diagn Lab Immunol 1 (1994) 32-37.
21. Marangoni A, Sambri V, Storni E, D'Antuono A, Negosanti M, Cevenini R. **Treponema pallidum surface immunofluorescence assay for serologic diagnosis of syphilis.** Clin Diagn Lab Immunol 7 (2000) 417-421.
22. Muller I, Brade V, Hagedorn HJ, Straube E, Schorner C, Frosch M, Hlobil H, Stanek G, Hunfeld KP. **Is serological testing a reliable tool in laboratory diagnosis of syphilis? Meta-analysis of eight external quality control surveys performed by the german infection serology proficiency testing program.** J Clin Microbiol 44 (2006) 1335-1341.
23. Meyer W, Scheper T, Lehmann Heike (Erfinder). **Selbstklebende Blotmembran.** EUROIMMUN Medizinische Labordiagnostika AG. Patent. Aktenzeichen 20215268.5 (2002).
24. Meyer W, Scheper T (Erfinder). **Vorrichtung zur Antikörperdiagnose mit kombinierten Membranen.** EUROIMMUN Medizinische Labordiagnostika AG. Patent. Aktenzeichen 20215270.7 (2002).
25. Morrin M, Rateike Martin, Müller M (Erfinder). **Lichtquelle für ein Auflichtfluoreszenzmikroskop.** EUROIMMUN Medizinische Labordiagnostika AG. Patent. Aktenzeichen 202004010121.1 (2004).



26. Müller M, Wessel S, Morrin M (Erfinder). **Konstante Lichtquelle für die Fluoreszenzmikroskopie.** EUROIMMUN Medizinische Labordiagnostika AG. Patent. Aktenzeichen DE 10 2006 027 518.7 (2006).
27. Stöcker W, Rateike M, Morrin M. (Erfinder). **Verfahren zur Herstellung Festphasen-gebundener Bioreagenzien.** EUROIMMUN Medizinische Labordiagnostika AG. Patent. Aktenzeichen PCT/EP2005/000974 - EP 1718 948 (2005).
28. Young H, Moyes A, McMillan A, Patterson J. **Enzyme immunoassay for anti-treponemal IgG: screening or confirmatory test?** J Clin Pathol 45 (1992) 37-41.
29. Enders M, Hagedorn HJ. **Syphilis in pregnancy.** [Article in German] Z Geburtshilfe Neonatol 206 (2002) 131-137.
30. Hagedorn HJ. **MiQ 16/2001 Qualitätsstandards in der mikrobiologisch-infektiologischen Diagnostik: Syphilis.** Urban & Fischer Verlag München Jena. (2001).
31. Hagedorn HJ. **Aktuelle Aspekte der Syphilisdiagnostik.** Immun Infekt 21 (1993) 94-99.
32. Hagedorn HJ. **Serodiagnostik der Syphilis.** Diagnose u. Labor 45 (1995) 94-104.
33. Müller F, Hagedorn HJ. **Syphilis.** In: Thomas L (Hrsg) Labor und Diagnose. TH-Books Frankfurt/Main (1998) 1232-1241.
34. Schmidt BL, Edjlalipour M, Luger A. **Comparative evaluation of nine different enzyme-linked immunosorbent assays for determination of antibodies against Treponema pallidum in patients with primary syphilis.** J Clin Microbiol 38 (2000) 1279-1282.
35. Meyer PM, Eddy T, Baughn RE. **Analysis of Western Blotting (Immunoblotting) Technique in Diagnosis of Congenital Syphilis.** J Clin Microbiol 32 (1994) 629-633.
36. Angue Y, Yaueib A, Mola G, Duke T, Amoa AB. **Syphilis serology testing: a comparative study of Abbot Determine, Rapid Plasma Reagin (RPR) card test and Venereal Disease Research Laboratory (VDRL) methods.** P N G Med J 48 (2005) 168-173.
37. Dang Q, Feng J, Lu X, Zhang X, Xu H, Liu C, Nu X. **Evaluation of specific antibodies for early diagnosis and management of syphilis.** Int J Dermatol 45 (2006) 1169-1171.
38. Stöcker W. TITERPLANE **Vorrichtung zur Durchführung von Mikroanalysen.** Europäisches Patent Nr. EP 0 018 435 (1979). Übersetzt ins Englische, Französische und Schwedische.
39. Stöcker W. TITERPLANE **Apparatus and method for simultaneously mixing specimens for performing microanalyses.** USA-Patent Nr. 4,339,241 (1980/1982); patentiert auch in Japan.
40. Mabey D, Peeling RW, Ballard R, Benzaken AS, Galban E, Changanlucha J, Everett D, Balira R, Fitzgerald D, Joseph P, Nerette S, Li J, Zheng H. **Prospective, multi-centre clinic-based evaluation of four rapid diagnostic tests for syphilis.** Sex Transm Infect 82 (2006) 13-16.
41. Serwin AB, Kohl PK, Chodynicka B. **The centenary of Wassermann reaction--the future of serological diagnosis of syphilis, up-to-date studies.** [Article in Polish] Przegl Epidemiol 59 (2005) 633-640.
42. Cervera R, Asherson RA. **Antiphospholipid syndrome associated with infections: clinical and microbiological characteristics.** Immunobiology 210 (2005) 735-741.

### Liability

The test kit, including original accessories, must only be used in accordance with the intended use. EUROIMMUN accepts no liability for any other use (e.g. non-compliance with the instructions for use and improper use) or for resulting damages.



## **Technical Support**

In case of technical problems you can obtain assistance via the EUROIMMUN website (<https://www.euroimmun.de/en/contact/>).

## **Additional information**

Regulatory information for customers in the European Union: Please observe the obligation to report any serious incidents occurring in connection with this product to the competent authorities and to EUROIMMUN.

